

References for Abstract - Effect of Ocrelizumab on Antibody Responses to EBV

1. Ascherio, A., Munch, M., 2000. Epstein-Barr virus and multiple sclerosis. *Epidemiology* 11, 220–224.
2. Almohmeed, Y.H., Avenell, A., Aucott, L., Vickers, M.A., 2013. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and multiple sclerosis. *PLoS One* 8, e61110.
3. Handel, A.E., Williamson, A.J., Disanto, G., Handunnetthi, L., Giovannoni, G., Ramagopalan, S.V., 2010. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. *PLoS One* 5, e12496.
4. Sundstrom, P., Juto, P., Wadell, G., Hallmans, G., Svenningsson, A., Nystrom, L., et al., 2004. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. *Neurology* 62, 2277–2282.
5. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelmann JH, Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. *Arch Neurol* 2006; 63: 839–844.
6. Munger, K., Levin, L., O'Reilly, E., Falk, K., Ascherio, A., 2011. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. *Mult. Scler.* 17, 1185–1193.
7. Dooley, M.M., de Gannes, S.L., Fu, K.A., Lindsey, J.W., 2016. The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins. *J. Neuroimmunol.* 299, 147–151.
8. Serafini, B., Rosicarelli, B., Franciotta, D., Magliozzi, R., Reynolds, R., Cinque, P., et al., 2007. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. *J. Exp. Med.* 204, 2899–2912.
9. Serafini, B., Severa, M., Columba-Cabezas, S., Rosicarelli, B., Veroni, C., Chiappetta, G., et al., 2010. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. *J. Neuropathol. Exp. Neurol.* 69, 677–693.
10. Serafini, B., Muzio, L., Rosicarelli, B., Aloisi, F., 2013. Radioactive in situ hybridization for Epstein-Barr virus-encoded small RNA supports presence of Epstein-Barr virus in the multiple sclerosis brain. *Brain* 136, e233.
11. Tzartos, J.S., Khan, G., Vossenkamper, A., Cruz-Sadaba, M., Lonardi, S., Sefia, E., et al., 2012. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. *Neurology* 78, 15–23.
12. Lassmann, H., Niedobitek, G., Aloisi, F., Middelorp, J.M., 2011. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue—report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. *Brain* 134, 2772–2786.
13. Esposito, M., Venkatesh, V., Otvos, L., Weng, Z., Vajda, S., Banki, K., et al., 1999. Human transaldolase and cross-reactive viral epitopes identified by autoantibodies of multiple sclerosis patients. *J. Immunol.* 163, 4027–4032.
14. Sospedra, M., Martin, R., 2006. Molecular mimicry in multiple sclerosis. *Autoimmunity* 39, 3–8.
15. Lindsey, J.W., deGannes, S.L., Pate, K.A., Zhao, X., 2016. Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L. *Mol. Immunol.* 69, 7–12.

16. Lindsey, J.W., 2017. Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins. *J. Neuroimmunol.* 310, 131-134.
17. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *N Engl J Med* 2017; 376:221-34.
18. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. *N Engl J Med* 2017; 376:209-20.